Mexico Agrees to Host Irans World Cup Squad Amid USIran Tensions Says President Sheinbaum CCI Approves LFPLLed Consortiums Stake Acquisition in Restaurant Brands Asia JPMorgans Jamie Dimon Wall Street Gung Ho but Bank Sees 1 Billion Expense Increase in 2026 Sebi Chief Tuhin Kanta Pandey Advocates Bond ETFs and Tokenisation as Corporate Debt Fundraising Approaches Rs 9 Lakh Crore Prediction Market Investment Surge Continues Despite Regulatory Uncertainty Earnings Calls Reveal Firm Commitment Diversified Energy Strikes Deal to Acquire Maverick Natural Resources in Permian Basin Expansion First Mid Bancshares FMBH Q1 2026 Earnings EPS Surpasses Expectations by 531 Amid Steady Performance RYAAY Q1 2026 Earnings Wide EPS Miss Still Spurs Positive Market Reaction CNH Q1 2026 Earnings EPS Beats Estimates by 75 Stock Declines Slightly CURR Q3 2025 Earnings Strong EPS Surprise as Profitability Emerges Revenue Details Not Disclosed XGN Q1 2026 Earnings EPS Beat Highlights Cost Discipline Amid Revenue Uncertainty John Hancock Premium Dividend Fund PDT Edges Higher as YieldSeekers Take Notice Cellyan Biotechnology HKPD Drops 36 as Shares Approach Critical 050 Support CytoMed Therapeutics GDTC Drops 738 Key Support Levels in Focus Amid Selling Pressure OXSQH Holds Steady at 2502 as FixedIncome Investors Seek Yield Cementos Pacasmayo CPAC Holds Steady Near Resistance as Investors Weigh Sector Fundamentals Kardigan Files for IPO to Advance Heart Disease Drug Pipeline in 2026 Jardine Matheson Acquires Australias IMED Radiology in 24 Billion Healthcare Expansion Beyond Inc to Acquire Buy Buy Baby Brand Rights Reuniting with Bed Bath Beyond Geopolitical Frictions Taiwan Arms Sales Emerge as Pivotal Point in TrumpXi Summit Natural Gas Faces Headwinds as APAC Flows and Storage Competition Reshape Market Dynamics Why One Wall Street Analyst Suggests Micron Shares Could Gain 85 on AI Memory Demand Perpetua Resources Secures 29 Billion US Loan for Idaho Gold and Antimony Mine XTNT Q1 2026 Earnings EPS Misses Estimates Despite Stock Gain Design Therapeutics DSGN Declines 2 as Shares Test Key Support Levels